Pacira BioSciences, Inc.
No SEC Form 4 filings for $PCRX in the last 30 days.
See all $PCRX insider activity →Pacira (PCRX) discussed its Q2 2026 earnings call, focusing on EXPAREL commercial momentum and pipeline progress. It said it secured UnitedHealthcare coverage for separate reimbursement, reaching 150 million covered lives by midyear toward a 160 million goal. Pacira also reported iovera divestiture completion to Zimmer Biomet on July 31 and outlined Phase 2 PCRX-201 Part B enrollment and Phase 3 ZILRETTA timing.
Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pcrx-06302026x991.htm EX-99.1 Document FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Second Quarter 2026 Financial Results -- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber com
Pacira BioSciences (NASDAQ: PCRX) said UnitedHealthcare will provide separate reimbursement for EXPAREL (bupivacaine liposome injectable suspension) in outpatient settings, including hospital outpatient departments and ambulatory surgery centers. Pacira said this allows reimbursement outside surgical bundles for eligible members and expands access across ~40 million covered lives.
Over the past 7 days, alphai's AI scored 1 news story mentioning PCRX (Pacira BioSciences, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PCRX coverage spans earnings, market movers and corporate actions.
Near-term trading focus is EXPAREL commercial momentum from expanded payer coverage plus execution on pipeline readouts (PCRX-201 Part A top-line later this year, ZILRETTA Phase 3 later this year).
Near-term sentiment should skew positive on revenue/earnings prints and the closed iovera transaction, but investors may focus on adjusted EBITDA softness and the post-divestiture earnings mix.
Separate reimbursement expansion with a major payer should support broader EXPAREL utilization and reduce adoption friction.
Deal terms and expected Q3 2026 close create a near-term catalyst for PCRX valuation and balance-sheet use of proceeds.
Deal economics (upfront $70M plus up to $70M contingent) and a Q3 2026 expected close create a clear catalyst for PCRX valuation and risk profile.
alphai scores every news story that mentions PCRX with an AI model for sentiment and relevance, and aggregates insider trades from Pacira BioSciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pacira (PCRX) discussed its Q2 2026 earnings call, focusing on EXPAREL commercial momentum and pipeline progress. It said it secured UnitedHealthcare coverage for separate reimbursement, reaching 150 million covered lives by midyear toward a 160 million goal. Pacira also reported iovera divestiture completion to Zimmer Biomet on July 31 and outlined Phase 2 PCRX-201 Part B enrollment and Phase 3 ZILRETTA timing.
7 min readPacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pcrx-06302026x991.htm EX-99.1 Document FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Second Quarter 2026 Financial Results -- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber com
6 min readPacira BioSciences (NASDAQ: PCRX) said UnitedHealthcare will provide separate reimbursement for EXPAREL (bupivacaine liposome injectable suspension) in outpatient settings, including hospital outpatient departments and ambulatory surgery centers. Pacira said this allows reimbursement outside surgical bundles for eligible members and expands access across ~40 million covered lives.
4 min readPacira BioSciences (PCRX) said it will sell its iovera business to Zimmer Biomet (ZBH) for up to $140M. The deal includes a $70M upfront payment and up to $70M in milestone payments through Dec. 31, 2031, with collaboration on a spasticity program. Closing is expected in Q3 2026; Pacira plans to use net proceeds to strengthen its balance sheet. PCRX rose premarket; ZBH fell.
4 min readPacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. pcrx-20260628 6/28/2026 0001396814 false 0001396814 2026-06-28 2026-06-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
2 min readPacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 pacira2014amendedandrestat.htm EX-10.1 Document Exhibit 10.1 PACIRA BIOSCIENCES, INC. AMENDED AND RESTATED 2014 EMPLOYEE STOCK PURCHASE PLAN (As approved by stockholders on June 9, 2026) SECTION 1. PURPOSE The purposes of the Amended and Restated 2014 Employee Stock Pur
2 min readWILLIAMS KRISTEN (Chief Administrative Officer) sold 10,259 shares of Pacira BioSciences, Inc. (PCRX) at $22.27 ($0.23M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
1 min readPacira BioSciences urged shareholders to vote the BLUE proxy card “FOR” its three director nominees ahead of its June 9, 2026 annual meeting. The company said proxy advisers ISS, Glass Lewis and Egan-Jones recommend “FOR” Pacira’s nominees and “AGAINST” DOMA Perpetual’s nominees. Pacira cited 2025 record revenue and Q1 2026 EXPAREL revenue of $143.3M (+5% YoY), ZILRETTA $26.8M (+15%) and iovera° $6.2M (+21%).
4 min readPacira Biosciences (PCRX) reported Q1 2026 results on April 30: revenue rose 5% YoY to $177.4M, above the $172.46M projection. Exparel sales volume increased 7% and accounted for over 80% of revenue. GAAP net income was $2.9M vs. $4.8M prior year; cash totaled $202.2M and $50M was spent on buybacks. Full-year revenue guidance is $745M–$770M, with Exparel $600M–$620M.
5 min readPacira BioSciences said Glass Lewis recommended shareholders vote “FOR” all three of its director nominees—Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans—and “AGAINST” the three nominees proposed by DOMA Perpetual Capital Management on the BLUE proxy card ahead of the June 9, 2026 annual meeting. Glass Lewis cited Pacira’s 37% one-year total shareholder return in 2025 and 23.8% cumulative since its 5x30 strategy launch.
4 min read
